Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with bortezomib for newly diagnosed multiple myeloma (A phase III trial)